Table 1.
Baseline characteristics of the study population (n = 11)
|
Variable | |
|---|---|
| Clinical parameters | |
| Male, n (%) |
4 (36.4) |
| Age (yrs) |
92.6 ± 1.3 |
| BMI (kg/m2) |
28.6 ± 3.0 |
| Hypertension, n (%) |
9 (81.8) |
| Dyslipidemia (%) |
9 (81.8) |
| Smoker, n (%) |
3 (27.3) |
| Diabetes mellitus, n (%) |
7 (63.6) |
| Renal insufficiency (creatinine level > 1.5mg/dl), n (%) |
6 (54.5) |
| Chronic hemodyalisis, n (%) |
2 (18.2) |
| Chronic obstructive pulmonary disease, n (%) |
2 (18.2) |
| New York Heart Association functional class (grade) |
3.2 ± 0.8 |
| Logistic EuroSCORE (%) |
32.0 ± 9.5 |
| STS score (%) |
25.3 ± 9.7 |
| Dyspnoe, n (%) |
11 (100) |
| Angina, n (%) |
4 (36.4) |
| Syncope, n (%) |
4 (36.4) |
| Cardiac decompensation, n (%) |
5 (45.5) |
| Pulmonal artery systolic pressure (mmHg) |
40.8 ± 18.7 |
| Porcelain aorta, n (%) |
0 (0) |
| Ischemic heart disease, n (%) |
8 (72.7) |
| Previous percutaneous coronary intervention, n (%) |
6 (54.5) |
| Previous coronary artery bypass graft surgery, n (%) |
4 (36.4) |
| Peripheral vessel disease, n (%) |
2 (18.2) |
| Previous stroke, n (%) |
2 (18.2) |
|
Laboratory findings | |
| Hemoglobin (mg/dl) |
7.8 ± 1.2 |
| Hematokrit (%) |
37.7 ± 4.8 |
| Creatinine (μmol/l) |
183.9 ± 223.6 |
| MDRD |
48.2 ± 24.6 |
|
Medication | |
| Aspirin |
7 (63.6) |
| ACE-Inhibitor |
7 (63.6) |
| ARB |
2 (18.2) |
| Beta-Blocking agent |
8 (72.7) |
| Ca-chanel blocker |
3 (27.3) |
| Antiarythmic agent |
0 (0) |
| Statin | 7 (63.6) |